Now that AbbVie has officially reversed course on its plans to recommend shareholders for the $54 billion bid for Shire, numerous ‘what next’ questions are being asked about the future for both drug makers, and understandably so. The drug maker is backing away now that the U.S. Treasury Department issued new rules to prevent so-called inversion deals that involve shifting corporate domiciles to foreign countries and lower corporate tax rates.. Yet the AbbVie executive team remained openly bullish about forging ahead with the Shire deal even after the new rules were issued and were publicly released in filings with the U.S. Securities and Exchange Commission. This brings us to our quote of the week…